Work with thought leaders and academic experts in Drug Discovery
Companies can benefit from working with academic researchers in Drug Discovery in several ways. These experts can provide valuable insights and expertise in developing new drugs, conducting preclinical and clinical trials, and optimizing drug discovery processes. They can also offer access to cutting-edge technologies and research facilities, as well as collaborations with other academic institutions and industry partners. Additionally, academic researchers can help companies stay updated with the latest advancements in the field and provide guidance on regulatory requirements and intellectual property issues. By collaborating with academic researchers in Drug Discovery, companies can accelerate their drug development efforts, enhance their scientific credibility, and gain a competitive edge in the market.
Researchers on NotedSource with backgrounds in Drug Discovery include Dr. Everson A Nunes, Ph.D., Ajay Badhan, Regan Hamel, Aimee Eggler, Elena Shersher, Ph.D., Dr. David Siderovski, Ph.D., and Maurice O'Sullivan.
Dr. Everson A Nunes, Ph.D.
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Most Relevant Research Expertise
Other Research Expertise (39)
About
Most Relevant Publications (1+)
97 total publications
Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes
Current Drug Targets / Mar 30, 2017
Nunes, E., & Rafacho, A. (2017). Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes. Current Drug Targets, 18(6), 619–628. https://doi.org/10.2174/1389450117666151209120345
See Full Profile
Ajay Badhan
Research Biologist, Lethbridge Research Center, Canada
Most Relevant Research Expertise
Other Research Expertise (26)
About
Most Relevant Publications (1+)
29 total publications
Designer Plants for Biofuels: A Review
Current Metabolomics / Mar 02, 2016
Badhan, A., & McAllister, T. (2016). Designer Plants for Biofuels: A Review. Current Metabolomics, 4(1), 49–55. https://doi.org/10.2174/2213235x03666141226213656
See Full Profile
Regan Hamel
Senior bioinformatics scientist, specializing in single cell omics in the context of cellular reprogramming and neuroinflammation
Most Relevant Research Expertise
Other Research Expertise (12)
About
Most Relevant Publications (1+)
12 total publications
Combination of In Situ Lcn2 pRNA-RNAi Nanotherapeutics and iNSC Transplantation Ameliorates Experimental SCI in Mice
Molecular Therapy / Dec 01, 2020
Braga, A., Bandiera, S., Verheyen, J., Hamel, R., Rutigliani, C., Edenhofer, F., Smith, J. A., & Pluchino, S. (2020). Combination of In Situ Lcn2 pRNA-RNAi Nanotherapeutics and iNSC Transplantation Ameliorates Experimental SCI in Mice. Molecular Therapy, 28(12), 2677–2690. https://doi.org/10.1016/j.ymthe.2020.08.001
See Full Profile
Aimee Eggler
Professor of Chemistry and Biochemistry at Villanova University
Most Relevant Research Expertise
Other Research Expertise (18)
About
Most Relevant Publications (3+)
25 total publications
Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding
Bioorganic & Medicinal Chemistry Letters / Nov 01, 2013
Turlington, M., Chun, A., Tomar, S., Eggler, A., Grum-Tokars, V., Jacobs, J., Daniels, J. S., Dawson, E., Saldanha, A., Chase, P., Baez-Santos, Y. M., Lindsley, C. W., Hodder, P., Mesecar, A. D., & Stauffer, S. R. (2013). Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding. Bioorganic & Medicinal Chemistry Letters, 23(22), 6172–6177. https://doi.org/10.1016/j.bmcl.2013.08.112
Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease
Journal of Medicinal Chemistry / Jan 03, 2013
Jacobs, J., Grum-Tokars, V., Zhou, Y., Turlington, M., Saldanha, S. A., Chase, P., Eggler, A., Dawson, E. S., Baez-Santos, Y. M., Tomar, S., Mielech, A. M., Baker, S. C., Lindsley, C. W., Hodder, P., Mesecar, A., & Stauffer, S. R. (2013). Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease. Journal of Medicinal Chemistry, 56(2), 534–546. https://doi.org/10.1021/jm301580n
Insecticidal Activity of Cyanohydrin and Monoterpenoid Compounds
Molecules / Apr 03, 2000
Peterson, C., Tsao, R., Eggler, A., & Coats, J. (2000). Insecticidal Activity of Cyanohydrin and Monoterpenoid Compounds. Molecules, 5(12), 648–654. https://doi.org/10.3390/50400648
See Full Profile
Dr. David Siderovski, Ph.D.
Professor of Computational Pharmacology; Chair of HSC SBS Dept. of Pharmacology & Neuroscience
Most Relevant Research Expertise
Other Research Expertise (25)
About
Most Relevant Publications (4+)
94 total publications
Regulators of G-Protein signalling as new central nervous system drug targets
Nature Reviews Drug Discovery / Mar 01, 2002
Neubig, R. R., & Siderovski, D. P. (2002). Regulators of G-Protein signalling as new central nervous system drug targets. Nature Reviews Drug Discovery, 1(3), 187–197. https://doi.org/10.1038/nrd747
Established and Emerging Fluorescence-Based Assays for G-Protein Function: Ras-Superfamily GTPases
Combinatorial Chemistry & High Throughput Screening / Jun 01, 2003
Rojas, R., Kimple, R., Rossman, K., Siderovski, D., & Sondek, J. (2003). Established and Emerging Fluorescence-Based Assays for G-Protein Function: Ras-Superfamily GTPases. Combinatorial Chemistry & High Throughput Screening, 6(4), 409–418. https://doi.org/10.2174/138620703106298509
Established and Emerging Fluorescence-Based Assays for G-Protein Function: Heterotrimeric G-Protein Alpha Subunits and Regulator of G-Protein Signaling (RGS) Proteins
Combinatorial Chemistry & High Throughput Screening / Jun 01, 2003
Kimple, R., Jones, M., Shutes, A., Yerxa, B., Siderovski, D., & Willard, F. (2003). Established and Emerging Fluorescence-Based Assays for G-Protein Function: Heterotrimeric G-Protein Alpha Subunits and Regulator of G-Protein Signaling (RGS) Proteins. Combinatorial Chemistry & High Throughput Screening, 6(4), 399–407. https://doi.org/10.2174/138620703106298491
A High Throughput Fluorescence Polarization Assay for Inhibitors of the GoLoco Motif/G-alpha Interaction
Combinatorial Chemistry & High Throughput Screening / Jun 01, 2008
Kimple, A., Yasgar, A., Hughes, M., Jadhav, A., Willard, F., Muller, R., Austin, C., Inglese, J., Ibeanu, G., Siderovski, D., & Simeonov, A. (2008). A High Throughput Fluorescence Polarization Assay for Inhibitors of the GoLoco Motif/G-alpha Interaction. Combinatorial Chemistry & High Throughput Screening, 11(5), 396–409. https://doi.org/10.2174/138620708784534770
See Full Profile
Maurice O'Sullivan
University College Cork, School of Food and Nutritional Sciences
Most Relevant Research Expertise
Other Research Expertise (33)
About
Most Relevant Publications (1+)
85 total publications
Dietary Compounds Influencing the Sensorial, Volatile and Phytochemical Properties of Bovine Milk
Molecules / Dec 19, 2019
Clarke, H. J., Griffin, C., Rai, D. K., O’Callaghan, T. F., O’Sullivan, M. G., Kerry, J. P., & Kilcawley, K. N. (2019). Dietary Compounds Influencing the Sensorial, Volatile and Phytochemical Properties of Bovine Milk. Molecules, 25(1), 26. https://doi.org/10.3390/molecules25010026
See Full Profile
Example Drug Discovery projects
How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on Drug Discovery?
Development of Novel Drug Candidates
An academic researcher in Drug Discovery can collaborate with a company to develop novel drug candidates. By leveraging their expertise in molecular biology, pharmacology, and medicinal chemistry, the researcher can identify potential drug targets, design and synthesize new compounds, and evaluate their efficacy and safety. This collaboration can help the company expand its drug pipeline and bring innovative therapies to the market.
Optimization of Drug Discovery Processes
Companies can collaborate with academic researchers to optimize their drug discovery processes. The researcher can provide insights into the latest techniques and technologies for high-throughput screening, virtual screening, and computational modeling. They can also help in streamlining the hit-to-lead and lead optimization stages, improving the efficiency and success rate of drug discovery projects.
Preclinical and Clinical Trials
Academic researchers with expertise in Drug Discovery can assist companies in conducting preclinical and clinical trials. They can design and execute studies to evaluate the safety, efficacy, and pharmacokinetics of potential drug candidates. Their knowledge of regulatory requirements and ethical guidelines ensures that the trials are conducted in compliance with industry standards.
Collaborations with Other Academic Institutions
By collaborating with academic researchers, companies can tap into a network of other experts and institutions in the field of Drug Discovery. These collaborations can lead to joint research projects, knowledge sharing, and access to specialized resources and facilities. Such partnerships can foster innovation and accelerate the development of new drugs.
Intellectual Property and Regulatory Guidance
Academic researchers can provide guidance on intellectual property (IP) and regulatory matters related to drug discovery. They can help companies navigate the complex landscape of patents, copyrights, and licensing agreements. Additionally, they can offer insights into regulatory requirements and assist in preparing documentation for regulatory submissions, ensuring compliance with relevant laws and regulations.